The aim of the study is to develop a drug therapy to halt the degeneration process in retinal dystrophies. Specifically, we aim to prove our hypothesis on the cause-and-effect relationships of the mechanisms of action of our drug treatment candidate and to obtain more information on the efficacy of the treatment, especially in retinal diseases related to the Finnish disease heritage. Although the first clinical trial should be carried out with oral drugs to speed up the process, the project is also working on innovative eye delivery techniques so that in the future, drugs to retinal diseases can be administered directly into the eye. The treatment based on drug repurposing can lead to clinical applications on an accelerated schedule compared to the traditional drug development pipeline.

2025